Altimmune, Inc. (ALT)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$3.42+5.88%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · ALT
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 380.1% |
| Our one-year growth estimate | diamond | 91.7% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 288.4 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
ALT — litigation filed
Dated 2026-06-16
Other Events. On June 16, 2026, Altimmune, Inc. (the “Company”) announced plans to relocate its corporate headquarters from Gaithersburg, Maryland to Morristown, New Jersey later this year. The new headquarters is in a geography with a strong presence of biopharmaceutical companies, which is expected to support the Company’s ability to attract top-tier talent in its hybrid business model, as the Company continues its growth as a late-stage development company. The Company has entered into an…
Why it matters: The move aims to attract talent in a strong biopharmaceutical area. A successful move could improve operations.
Supportive ifThe move to Morristown, New Jersey, is successful, with new hires in key roles.
Worry ifDelays or problems in the move could hurt talent acquisition.
Why it matters: Completing enrollment shows strong interest. This could help collect data faster for ALD.
Supportive ifEnrollment in the RESTORE trial finished early. This shows strong interest from patients.
Worry ifEnrollment in the RESTORE trial is delayed or fails to meet expectations.
Why it matters: The move to New Jersey could attract talent and improve operations. This is key for growth.
Supportive ifNews of new hires or partnerships after moving to New Jersey.
Worry ifNo major news or new talent after the move.
Why it matters: If the health care sector shows renewed growth, it could benefit Altimmune. This signals a better environment for the company.
Supportive ifSector revenue growth speeds up again. This shows a good trend.
Worry ifSector revenue growth slows down. This means there are still challenges.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$199 on $10,000 · ±2.0% | How much price usually moves either way. |
| Bad day | $529 loss on $10,000 · 5.3% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $5,809 loss on $10,000 · 58.1% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Earnings results will show how the company is doing financially. This can affect stock prices.
Watch forEarnings results show that revenue is growing or that operations are improving.
Also watch forEarnings results show that revenue is falling or that financial conditions are getting worse.
Why it matters: Topline data will show if pemvidutide works for alcohol use disorder. Good results could help with future approvals.
Supportive ifTopline data shows a big drop in heavy drinking days compared to placebo.
Worry ifTopline data shows no big drop in heavy drinking days compared to placebo.
Why it matters: Topline data will show how well pemvidutide works for alcohol use disorder. This could affect future trials and approvals.
Supportive ifTopline data will be reported in Q3 2026. It will show positive results.
Worry ifTopline data shows negative results. It may not be released on time.
Why it matters: High operating losses mean the company has money problems. This can hurt its stability.
Worry ifOperating losses are worse than -$24.2M in the next financial results.
Less concerning ifOperating losses better than -$24.2M show the company is managing costs well.
Why it matters: This data shows how pemvidutide helps patients with liver disease from alcohol. Good results may help in talks with regulators.
Supportive ifTopline data from the RESTORE trial shows a big change in liver stiffness at Week 48.
Worry ifTopline data shows no big change in liver stiffness at Week 48.
Why it matters: Updates on pemvidutide trials show Altimmune's product is making progress. This could help investors.
Supportive ifA press release confirms good results or key steps in the pemvidutide trials.
Worry ifNo updates or bad results from the pemvidutide trials.
Why it matters: Earnings results show how well the company is doing with money and operations.
Watch forThe earnings report shows more revenue or fewer losses than in Q1.
Also watch forThe earnings report shows ongoing losses or less revenue.
Why it matters: The FDA's response will guide Altimmune's next steps for pemvidutide in treating alcohol use disorder. This could impact future trials and market potential.
Watch forFDA provides clear guidance on the path forward for pemvidutide in AUD.
Also watch forThe FDA has big worries about how well pemvidutide works or its safety for AUD.
Why it matters: How Altimmune reacts to strong peers like Lilly and AbbVie will show its competitive position. This affects investor confidence.
Watch forAltimmune announces a new partnership or product. This helps its market position.
Also watch forNo big news or partnerships announced. This lets competitors get ahead.
Why it matters: Relocating to a biopharma hub may help attract talent and improve operations. This could impact growth.
Watch forNew hires or partnerships were announced after the headquarters move.
Also watch forNo big changes or talent hiring happened after the move.
Why it matters: The start of this trial is critical for pemvidutide's development in treating MASH. It signals commitment to advancing the drug.
Supportive ifThe trial starts as planned. Patient enrollment begins on schedule.
Worry ifThe trial starts late. Enrollment is much lower than expected.
Why it matters: The outcome of the lawsuit could affect Altimmune's work and image.
Watch forThe lawsuit ends with a good result for Altimmune.
Also watch forThe lawsuit ends with a bad result or settlement against Altimmune.
Why it matters: The PERFORMA trial data will help us understand how well pemvidutide treats MASH. Good results could show the treatment's market potential.
Supportive ifThe 52-week data from the PERFORMA trial shows strong results in treating MASH.
Worry ifThe 52-week data readout shows pemvidutide is not effective in treating MASH.
Why it matters: The upcoming earnings report will show cash position and costs. This is key for understanding financial health.
Watch forThe earnings report shows a smaller net loss or more cash compared to past quarters.
Also watch forThe earnings report shows a bigger net loss or less cash compared to past quarters.